Page results
-
The Integrated Children’s and Adolescent Service has been established to provide complementary care alongside orthodox treatments. The clinic sees children up to 18 years old with a wide variety of illnesses.
-
Information about the integrated general medicine service at the Royal London Hospital for Integrated Medicine.
-
Information about the integrated occupational therapy service at the Royal London Hospital for Integrated Medicine
-
This page aims to provide information about the syndrome haemophagocytic lymphohistiocytosis (HLH).
-
The Ataxia Centre brings together a team of specialists, with expertise in the diagnosis, management and research of all forms of ataxia.
-
We offer comprehensive assessment, diagnostic services and investigation for all forms of the disease including neuropsychology, neurophysiology, imaging, genetic testing, and tissue diagnosis.
-
A guide created by The Red Cell Network with expert patient insight from Elaine Tappin, Miriam Santos Freire and Nneka Smith.
-
The department specialises in the assessment and management of Complex Neuropsychiatric conditions occurring in the context of neurological disease.
-
A drop-in service providing support, practical advice and information.
-
Skeletal muscle channelopathies are rare neuromuscular diseases that cause symptoms of episodic muscle weakness/paralysis or cause difficulty in relaxing muscles (the muscle can feel stuck or cramped) once they are contracted.
File results
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments